SOLIGENIX, INC. Payments of Financing Costs
SOLIGENIX, INC. (SNGX) reported Payments of Financing Costs of -$40.74 thousand for the 12-month period ending 2011-12-31, per its 10-K filed 2013-02-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2013-02-26
- SOLIGENIX, INC. payments of financing costs for the quarter ending 2011-12-31 was $0.00.
- SOLIGENIX, INC. payments of financing costs for the quarter ending 2010-12-31 was $0.00.
- SOLIGENIX, INC. payments of financing costs for fiscal 2011 was -$40.74K.
- SOLIGENIX, INC. payments of financing costs for fiscal 2010 was $0.00.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$40.74K 10-K · filed 2013-02-26 | |
| 2011-09-30 | -$40.74K 10-Q · filed 2012-11-14 | ||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-27 | $0.00 10-K · filed 2012-03-27 | |
| 2010-09-30 | $0.00 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |